Clinical trial NCT00242216 - References

HIV Infections — "The Once A Day Protease Inhibitor Regimens"

Citation(s)

•   Bayés M, Rabasseda X, Prous JR
  Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Jul-Aug;25(6):483-506.
•   Bell TK, Holmes A, McCormack OE, Barnett BJ, Arduino RC
  Changing Genotypic Resistance Patterns and Demographics of Antiretroviral-Naïve HIV Patients in Houston: 1999-2006. 44th Annual Meeting of the Infectious Diseases Society of America (IDSA). Toronto,
•   Falcoz C, Jenkins JM, Bye C, Hardman TC, Kenney KB, Studenberg S, Fuder H, Prince WT
  Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers. J Clin Pharmacol. 2002 Aug;42(8):887-98.
•   Goldsmith DR, Perry CM
  Atazanavir. Drugs. 2003;63(16):1679-93; discussion 1694-5. Review.
•   Holmes A, Bell T, Barnett B, Arduino R
  Emerging resistance mutations in once-daily ritonavir-boosted protease inhibitor-containing antiretroviral regimens. 44th Annual Meeting of the Infectious Diseases Society of America (IDSA). Toronto, Canada. October
•   Holmes A, Lucke J, Maghidman S, Fernandez-Bussy S, Barnett B, Arduino R
  Tenofovir associated nephrotoxicity is dose-dependent ritonavir administration a co-factor? XVI International AIDS Conference. Toronto, Canada. August 13-18, 2006. Abstract TUPE0085.
•   Mannheimer SB, Matts J, Telzak E, Chesney M, Child C, Wu AW, Friedland G; Terry Beirn Community Programs for Clinical Research on AIDS
  Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. AIDS Care. 2005 Jan;17(1):10-22.
•   Murphy RL, Sanne I, Cahn P, Phanuphak P, Percival L, Kelleher T, Giordano M
  Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS. 2003 Dec 5;17(18):2603-14.
•   Rodriguez-French A, Boghossian J, Gray GE, Nadler JP, Quinones AR, Sepulveda GE, Millard JM, Wannamaker PG
  The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J Acquir Immune Defic Syndr. 2004 Jan 1;35(1):22-32.
•   Sax PE
  Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Atazanavir in treatment-experienced patients. AIDS Clin Care. 2003 Sep;15(9):78.
•   SOLO trial results released
  AIDS Patient Care STDS. 2003 Feb;17(2):95.
•   Vierling P, Greiner J
  Prodrugs of HIV protease inhibitors. Curr Pharm Des. 2003;9(22):1755-70. Review.

"PIQD: The Once a Day Protease Inhibitor Regimens." Ritonavir Boosted Atazanavir vs. Ritonavir Boosted Fosamprenavir Used in Combination With Tenofovir and Emtricitabine in HIV-1 Infected Antiretroviral Treatment-Naïve Patients.

Details for clinical trial NCT00242216